Fig. 3From: Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysisKaplan–Meier plots for validations of FRGS in non-chemotherapy and chemotherapy cohorts. A, B The DFS of patients with different CAF risk group in stage II/III patients without adjuvant chemotherapy: GSE39582 cohort (A) and TCGA cohort (B). C, D The DFS of patients with different CAF risk group in stage II/III patients with adjuvant chemotherapy: GSE39582 cohort (C) and TCGA cohort (D). E, F The DFS of patients with or without adjuvant chemotherapy in stage II/III patients with low CAF risk: GSE39582 cohort (E) and TCGA cohort (F). G, H The DFS of patients with or without adjuvant chemotherapy in stage II/III patients with high CAF risk: GSE39582 cohort (G) and TCGA cohort (H)Back to article page